Potential Value of Periostin as a Clinically Applicable Biomarker for Osteoarthritis

Qizhao Tan  
Peking University Third Hospital

Zhongwei Yang  
Peking University Third Hospital

Xing Xin  
Peking University International Hospital

Bin Yang  
Peking University Third Hospital

Zhili Xing  
Peking University International Hospital

Feng Li  
Peking University Third Hospital

Ke Zhang  
Peking University Third Hospital

Yun Tian (✉ tiany@bjmu.edu.cn)  
Peking University Third Hospital

Tengjiao Zhu (✉ Zhutj@bjmu.edu.cn)  
Peking University Third Hospital  
https://orcid.org/0000-0002-2748-3773

Research article

Keywords: Osteoarthritis, Biomarkers, Knee joint, Radiography, Risk factors

DOI: https://doi.org/10.21203/rs.3.rs-414612/v1

License: ☺️ This work is licensed under a Creative Commons Attribution 4.0 International License. 
Read Full License
Abstract

Background: Emerging knowledge has highlighted the role of periostin (POSTN) in osteoarthritis (OA) process; however, whether POSTN is suitable as a biomarker of OA remains unclear. Herein, we investigated the potential value of POSTN as a biomarker of OA.

Methods: We detected the expression of POSTN in the cartilage of ovariectomy (OVX)-OA rats and different compartments of the knee joint in patients with OA using immunohistochemistry and examined serum POSTN levels in patients with or without OA using enzyme-linked immunosorbent assay (ELISA). The associations among serum POSTN levels, clinical symptoms, and radiological severity were assessed according to the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores and, Kellgren-Lawrence (KL) grading, respectively. Finally, multivariable cumulative link models were established to evaluate the validity of serum POSTN as a predictor of knee OA.

Results: The significantly higher POSTN expression was found in OVX-OA rats than Sham rats, while, the expression of POSTN was significantly higher in the torn cartilage of patients with OA. However, the serum POSTN level did not differ significantly between patients with and without OA. Additionally, we found no remarkable associations between serum POSTN level and WOMAC scores and KL grading. Subsequent analysis revealed that serum POSTN was not a significant predictor of OA.

Conclusion: Thus, although POSTN may be involved in the initiation and progression of OA and local POSTN is valuable in disease diagnosis and distinguishing of the severity of disease, its serum level is not sufficient to serve as a candidate biomarker of OA given the current analysis technology.

Background

Osteoarthritis (OA) is characterized by progressive degeneration of cartilage, accompanied by synovitis, subchondral bone remolding, and damage to other joint structures. It has a worldwide prevalence and is the third leading cause of disability in the elderly [1, 2]. However, the pathophysiology of OA remains unclear, and its diagnosis relies on classically clinical symptoms and radiography, which usually reveals OA at the end-stage. Molecular changes have been reported to appear much earlier than the apparent clinical symptoms [3]. Hence, biomarkers of OA diseases has been a popular research trends [4]. However, to date, there have been no clinically applicable biomarkers in the diagnosis, monitoring, and prognosis of OA due to the heterogeneity in the pathogenesis and multiformity of the clinical symptoms [5].

Periostin (POSTN), belonging to the family of fasciclins, is a protein that originating from the osteoblasts [6]. It was initially identified in the periosteum and bone [7]. The role of POSTN has been widely researched, and several studies have suggested that POSTN might be related to OA [8, 9]. However, whether POSTN is a suitable biomarker of OA remains controversial.

Therefore, in the present study, we aimed to assess the rationality of POSTN as a potential biomarker for OA. First, POSTN involvement in the initiation and progression of OA was investigated by detecting the
expression level of POSTN in the cartilage of ovariectomy (OVX)-OA rats. Next, the involvement of POSTN in severity-related OA progression was explored by detecting the expression of POSTN in the damaged cartilage of the medial compartment and intact cartilage of the lateral compartment in patients with OA. The systematic level of POSTN was evaluated in patients with and without OA using Enzyme-linked immunosorbent assay (ELISA) to determine its suitability as a diagnostic marker. The clinical association between the serum POSTN level and symptomatic and radiographic severity of OA was also evaluated. Finally, multivariable cumulative link models were built to evaluate the validity of serum POSTN as a predictor of knee OA.

### Materials And Methods

#### Animal preparation

Ten 6-month-old female Sprague–Dawley (SD) rats were used in this study. After 1 week of adaptive feeding, dual ovariectomy (n=5) or Sham operation (n=5) were performed. Ten weeks post-operation, all rats were sacrificed and knee joints were harvested for follow-up bone histomorphometric assessment and histological analysis.

To confirm the success of the OVX model, the microstructure of the subchondral bone of the tibia was analyzed using micro-CT. Briefly, all the knee joints were carefully excised and scanned by high-resolution Micro-CT (Inveon, Siemens Medical Solutions USA, Inc., IL, USA). The following parameters of the scan were set and a high-med resolution scan was carried out: the voltage at 80-kV voltage and the current at 500-μA current, and 360 projections per 360°. The scanned data were reconstructed using the Inveon Acquisition Workplace software. The tibia subchondral trabecular bone below the subchondral bone plate extending to the epiphyseal line was selected as a region of interest (ROI). The bone volume/total volume (BV/TV) of the ROI was calculated to evaluate the structure of the subchondral bone.

#### Participant selection

Thirty-two patients with OA who underwent total knee joint arthroplasty (TKA) from January to July 2019 at the Peking University International Hospital orthopedics department were recruited. Patients with OA were diagnosed according to the American College of Rheumatology [10]. Eighteen patients in the arthroscopy surgery (ASS) group who had meniscus injuries or ligament injuries but with intact articular cartilages diagnosed by magnetic resonance imaging were selected as the control group. Clinical data were reviewed to preclude any forms of secondary OA. The following patients excluded: those with autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and ankylosing spondylitis; those who had a history of knee injuries within 1 month of intra-articular drug injection 6 months before surgery; those who underwent TKA revision or simultaneous bilateral knee OA. The Ethics Committee at Peking University International Hospital approved the study protocol (authorization number: 2018-069[BMR] ), and written informed consent was obtained from all patients before participation.

#### Clinical cartilage sample collection
The tibial plateaus was harvested from 32 end-stage patients with OA who underwent TKA. We differentiated the damaged cartilage zones in the medial plateau from the zones that were macroscopically intact in the lateral plateau. The macroscopically intact cartilage was considered as the control group (NC), and the lesion cartilage in the lateral plateau was viewed as the experimental group (AC).

**Histological analysis of POSTN**

For immunostaining, the clinical and rats samples were decalcified in EDTA for 6 weeks. Then, all the samples were dehydrated in a tissue automatic dehydration machine (Leica, Germany) and embedded in paraffin. The samples then were cut at a thickness of 5-\( \mu\)m. The sections were incubated with POSTN antibodies (Cat.No.19899-1-AP) for 2 hours at 37°C. The antigen–antibody interaction was detected using Chromogen diaminobenzidine kit (ZSGB-BIO, Beijing, China). Images were captured using a digital slide scanner (Hamamatsu, Japan). Image-Pro Plus (Version 6.0, Media Cybernetics, USA) was used to semi-quantitatively analyze the relative expression of the proteins in sections.

**Blood collection and serum level of POSTN detection**

To investigate if the systematic POSTN was different between patients with and without OA, blood was collected from the patients who underwent TKA (n=32) and those with meniscal or ligament injuries (n=18). The patients who underwent TKA were considered as the OA group and the latter was referred to as the Non-OA group. Blood was centrifuged at 4°C \( \times 1500 \) r/min for 15min to obtain the serum. The serum was stored at -80°C for the subsequent use. A Human ELISA Kit (Cat.No.AG-45B-0004-KI01) was used to measure the serum level of POSTN according to the manufacturer's protocol.

**Clinical symptom assessments**

To further demonstrate the potential value of POSTN as a biomarker of OA, the clinical associations between POSTN and symptomatic and radiographic OA were evaluated. The joint symptoms of all participants were assessed using Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). The WOMAC score was assessed using questionnaires, and the following subgroups were self-reported: knee joint pain, stiffness, and physical dysfunction.

**Knee joint radiographic assessments**

A 15-degree flexion, standing, anteroposterior view image was performed in the symptomatic knees of each participant. The radiographic severity of OA was assessed according to the Kellgren-Lawrence (KL) grading system [11]. The KL grading system was grouped into five grades, as previously reported. All preoperative radiographs were assessed by a single trained orthopedic specialist blinded to the patient's clinical and laboratory data. Participants with radiographic knee OA of KL grade \( \geq 2 \) in at least one knee were defined as patients with OA.

**Proportional odds logistic regression models**
To assess the predictive role of serum POSTN for OA, an odds logistic regression model was constructed. We also determined several other potential factors for OA. All risk factors included in the analysis of the predictors of OA were followed and divided into patient-related and laboratory-related risk factors. Age, sex, and body mass index were chosen as patient-related factors. The following laboratory-related risk factors were assessed: C-reactive protein, erythrocyte sedimentation rate, white blood cell count, neutrophil ratio, hemoglobin, platelet count, total protein, albumin, alanine aminotransferase, aspartate aminotransferase, creatinine, prothrombin time, international normalized ratios, activated partial thromboplastin time, fibrinogen, thrombin time, fibrin degradation product, D-dimer.

For analysis, the diagnosis was labeled as an ordinal categorical variable with levels of 0 and 1. Level-1 represented OA and level-0 was defined as non-OA. The descriptive summaries of each variable are shown in Table 1, and the numeric variables are presented as mean ± standard deviation. Two proportional odds logistic regression models were used to assess the extent of covariates in the diagnosis of knee OA. First, Model1 integrated all factors to analyze the prediction of knee OA. Model 2 selectively assessed laboratory-related factors as a predictor. The Akaike information criterion (AIC) was used to evaluate the different models. Variable importance plots were obtained by ranking each variable by the increase in AIC upon its removal[12]. AIC ≥2 represents a statistically better model [13]. Odds ratios (ORs) were reported as the ratio between the 75th and the 25th percentiles and significance was set at p<0.05. The statistical analysis above was performed using R software (R version 3.6.3).

Statistical analysis

The data were analyzed using GraphPad Prism 7.0 (GraphPad Software, Inc., La Jolla, CA, USA) and results are presented as mean ± standard error of the mean in immunohistochemistry and ELISA. The results of immunohistochemistry and ELISA were analyzed using a non-parametric Kruskal–Wallis test, and p values <0.05 were considered statistically significant. Linear regression analyses were used to examine the associations between serum POSTN level (the independent variable) and WOMAC scores and KL grading. The regression analyses performed were based on the assumption that the dependent variable was a function of the independent variables. Thus, the estimated associations were directional effects rather than causally undefined relations.

Results

Success of the OVX-OA rat model and increased POSTN expression in OVX-OA rats

The OVX-OA model was used to histologically confirm the differential localization of POSTN in OA tissues. The POSTN expression increased remarkably in the OVX rats compared to the Sham rats (Fig. 1c), which suggests that the POSTN might have been involved in the OA process.

To validate the success of OVX-OA models, the trabecular parameters of subchondral bone were analyzed by micro-CT. The results showed that BV/TV was significantly lower in OVX-OA rats than in
Sham rats (Fig. 1b), suggesting that osteoporosis was formed in OVX-OA rats and the OVX-OA model was successful.

**POSTN expression in the different compartments of OA clinical samples**

As shown in Fig. 2, the positive staining of POSTN was scarcely detected in the intact area of the cartilage in the lateral plateau. However, more positive staining of POSTN was found in damaged cartilage in the medial plateau. The semi-quantitative results showed that the experimental group had significantly elevated expressions than the control group. These findings indicate the possibility that POSTN may not only take part in the onset and process of OA, but also in severity-related disease progression.

**Serum levels of POSTN in patients with and without OA**

As shown in Fig. 3a, there was a slight increase in the plasma POSTN of patients with OA compared to the controls. However, no significant differences were observed (894.2±131.1 ng/mL vs 907.4±153.1 ng/mL, p > 0.05) between patients with and without OA.

**Association between the plasma POSTN and WOMAC scores**

OA symptoms were evaluated using the WOMAC scores. No significant association was found between the serum POSTN levels and total WOMAC scores (r=0.1997, p=0.1644) (Fig. 3b-e). None of the WOMAC grading system subgroups (pain [r=0.1472, p=0.3078], stiffness [r=0.002217, p=0.9878], and function [r=0.2226, p=0.1202]) showed significant association with serum POSTN levels.

**Association between plasma POSTN and Kellgren and Lawrence grade system**

The KL severity score was used to assess the association between serum POSTN and radiological changes. Based on the radiographic KL classification, patients with OA were categorized into three subgroups as per OA grading (KL grade 2:5; KL grade 3:8; KL grade 4:22). No remarkable association was found between the serum POSTN level and K-L grading (r=0.079, p=0.655) (Fig. 3f).

**Risk factors as predictors of OA**

We identified the predictive value of serum POSTN and several other risk factors that were potentially associated with OA. (Table 1) In model 1, the patient’s age appeared to be a major risk predictor of knee OA (p<0.001). When removing patient-related factors, serum POSTN seems was not a better laboratory-related factor in predicting knee OA (p>0.05) (Table 1, Fig. 4). Additionally, when adding laboratory-related risk factors to patient-related risk factors, the AIC suggested that adding these covariates would not yield a remarkable improvement in predicting OA (the AIC did not change remarkably). Similarly, other possible patient-related risk factors did not increase the risk of OA.

**Discussion**
Although POSTN has been suggested to be involved in the pathogenesis of OA, few clinical studies have examined its potential value as a biomarker in diagnosing, distinguishing the severity, and predicting the risk of developing the disease. To the best of our knowledge, this is the first epidemiological study to investigate the value of POSTN as an OA biomarker from above all aspects.

First, we established the OVX-OA model to verify whether POSTN is involved in the initiation and progression of OA. The OVX model has been confirmed to induce OA [14], and the tear in OVX-OA cartilage develops slowly, with characteristics similar to the process in the early stages of human OA. In this study, we found increased POSTN expression in the articular cartilage of OVX-OA rats compared to Sham rats, indicating that POSTN is involved in OVX-OA initiation. This finding is consistent with previous studies showing the detrimental role of POSTN in promoting inflammation and cartilage catabolism [8, 15].

Next, to confirm that POSTN was related to disease severity in the progression of OA, clinical samples from patients with OA were used. In the clinic, it can be found that a considerable portion of patients with OA has a predominantly torn cartilage in the medial compartment with intact cartilage in the lateral compartment [16]. The naturally different degrees of degradation in different compartments provided a good method to explore the different progression of the disease, eliminating the heterogeneity of different patients. In this study, the level of POSTN was highly expressed in the damaged cartilage of the medial compartment compared to the intact cartilage of the lateral compartment in clinical OA samples. This is in line with a previous study that reported that POSTN is mainly expressed near the erosive area of the cartilage in human OA [17].

The locally differential expression of POSTN suggested its participation in the initiation and progression of the disease and that it was valuable in disease diagnosis and distinguishing disease severity. However, the application value of local POSTN as a clinical biomarker of OA is limited. Because it is difficult and uneconomical to clinically harvest cartilage, invasive operations, which are necessary to harvest the local cartilage, can cause additional trauma and influence the operation time selection and postoperative infection of TKA that may be subsequently required [18]. On the contrary, the serum has better potential application value and is most commonly used in clinical settings.

Therefore, we further investigated whether the systemic level of serum POSTN could contribute to the diagnosis of OA. However, the data showed that the serum level of POSTN was not significantly different between patients with and without OA. The discrepancy between knee joint cartilage at the local level and serum level may be explained by the following reasons. First, the POSTN may undergo a clearance process from the local articular tissues to the serum, leading to an underestimation of its serum concentration [19]. Second, it has been reported that the tertiary structure of the FAS-1 domains could be modified by binding of a ligand [20], which may lead to a decrease in epitope recognition by antibodies in the POSTN assay. Moreover, the POSTN immunoassay could detect all isoforms of POSTN despite the presence of different isoforms, leading to a relatively higher level of POSTN, which was detected in local cartilage tissue.
To further determine whether the serum POSTN is in favor of distinguishing the severity of OA, we explored the association between POSTN and clinical characteristics of OA. The WOMAC score is the most commonly used disease-specific measurement of clinical symptoms in OA, and has 24 items with a total score and three subscales: pain, stiffness and physical function [21]. Our study demonstrated that serum POSTN was not positively associated with the total WOMAC score, pain and physical dysfunction. Several studies have shown a poor correlation between symptoms and radiographs in OA [22]. Thus, we further explored the relationship between serum POSTN and radiographs using the K-L grade system to evaluate anteroposterior weight-bearing knee radiographs of patients. We found no significant positive correlation between serum POSTN and K-L grade scores, suggesting that serum POSTN failed to reflect the severity of both symptoms and radiography in OA.

We used performed multivariable cumulative link models to verify the predictive value of POSTN as a risk factor. Our results showed that except for age as a valuable risk factor for OA, all other investigated risk factors including serum POSTN did not have remarkable value for predicting OA. This finding is consistent with the clinical settings that up to date there was no valuable and applicable laboratory factor to accurately predict OA development [23].

Notably, there are some limitations in the study. First, the sample size was relatively limited (n = 50), which could have to some extent lead to bias. Therefore, studies involving in larger sample sizes are needed to verify our preliminary findings. Second, the participants included in the OA group of this study were in the advanced stage of the disease. Thus, the predictive value of serum POSTN in the early stage of OA was unknown. Future longitudinal studies, especially in the early stage of OA, are required to confirm these findings.

In conclusion, we investigated the potential value of POSTN as an OA biomarker at the local and the serum level, in a rat animal model and clinical patients, and in all aspects of disease diagnosis, distinguishing the severity of the disease, and predicting the risk of developing the disease. Our results suggest that although POSTN may be involved in the initiation and progression of OA, local POSTN can be valuable for disease diagnosis and distinguishing the severity of the disease. However, its serum level is not sufficient to serve as a candidate biomarker of OA given the current technology for analysis.

**Abbreviations**

OA: Osteoarthritis; POSTN: Periostin; OVX: Ovariectomy; ELISA: Enzyme-linked immunosorbent assay; SD: Sprague–Dawley; ROI: Region of interest; TKA: Total keen joint arthroplasty; ASS: Arthroscopy surgery; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index; KL: Kellgren-Lawrence; AIC: Akaike information criterion; OR: Odds ratios

**Declarations**

**Ethics approval and consent to participate**
All procedures performed in studies involving human participants were in accordance with the ethical standards of the research committee of Peking University International Hospital (authorization number: 2018-069[BMR]) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All applicable institutional and/or national guidelines for the care and use of animals were followed. Informed consent was obtained from all individual participants included in the study.

Consent for publication

Not applicable

Competing interests

All authors declare that they have no competing interests.

Funding information

This work was supported by the grants from the Beijing Municipal Science&Technology Commission (Z181100001718195) and National Natural Science Foundation of China (82002030).

Authors’s Contributions

Qizhao Tan, Zhongwei Yang as the joint first authors who were involved in the subject design, clinical data collection as well as the analysis and discussion of experimental results. These authors contributed equally to this work. Yun Tian as one of the corresponding authors, was in charge of the subject design majority of the surgeries, and responsible for guiding the analysis and discussion of experimental results. Tengjiao Zhu, as one of the corresponding authors, actively participated in the subject design as well as the analysis and discussion of experimental results. Xing Xin, Bin Yang, Zhili Xing, Feng Li, and Ke Zhang as the co-authors were in charge of the surgeries mentioned in the article and made their contributions in the clinical samples collection as well as the clinical data collection.

Acknowledgments

We also gratefully acknowledge the generous help from members at Peking University Third Hospital Center Laboratory for the experiments support.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

1. Michaud CM, McKenna MT, Begg S, Tomijima N, Majmudar M, Bulzacchelli MT, Ebrahim S, Ezzati M, Salomon JA, Kreiser JG, Hogan M, Murray CJ, The burden of disease and injury in the United States
1996, Popul Health Metr 4 (2006) 11. 10.1186/1478-7954-4-11.

2. Liu CX, Gao G, Qin XQ, Deng CQ, Shen XJ. Correlation Analysis of C-terminal telopeptide of collagen type II and Interleukin-1beta for Early Diagnosis of Knee Osteoarthritis. Orthop Surg. 2020;12:286–94. 10.1111/os.12586.

3. Felson DT, Hodgson R. Identifying and treating preclinical and early osteoarthritis. Rheum Dis Clin North Am. 2014;40:699–710. 10.1016/j.rdc.2014.07.012.

4. Valdes AM. Metabolic syndrome and osteoarthritis pain: common molecular mechanisms and potential therapeutic implications. Osteoarthritis Cartilage. 2020;28:7–9. 10.1016/j.joca.2019.06.015.

5. Krasnokutsky S, Samuels J, Abramson SB. Osteoarthritis in 2007. Bull NYU Hosp Jt Dis. 2007;65:222–8.

6. Conway SJ, Izuhara K, Kudo Y, Litvin J, Markwald R, Ouyang G, Arron JR, Holweg CT, Kudo A. The role of periostin in tissue remodeling across health and disease. Cell Mol Life Sci. 2014;71:1279–88. 10.1007/s00018-013-1494-y.

7. Litvin J, Selim AH, Montgomery MO, Lehmann K, Rico MC, Devlin H, Bednarik DP, Safadi FF. Expression and function of periostin-isoforms in bone. J Cell Biochem. 2004;92:1044–61. 10.1002/jcb.20115.

8. Attur M, Yang Q, Shimada K, Tachida Y, Nagase H, Mignatti P, Statman L, Palmer G, Kirsch T, Beier F, Abramson SB. Elevated expression of periostin in human osteoarthritic cartilage and its potential role in matrix degradation via matrix metalloproteinase-13. FASEB J. 2015;29:4107–21. 10.1096/fj.15-272427.

9. Chinzei N, Brophy RH, Duan X, Cai L, Nunley RM, Sandell LJ, Rai MF. Molecular influence of anterior cruciate ligament tear remnants on chondrocytes: a biologic connection between injury and osteoarthritis. Osteoarthritis Cartilage. 2018;26:588–99. 10.1016/j.joca.2018.01.017.

10. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biemat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580–8. 10.1136/ard.2010.138461.

11. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis. 1957;16:494–502. 10.1136/ard.16.4.494.

12. Piuzzi NS, Strnad GJ, Sakr Esa WA, Barsoum WK, Bloomfield MR, Brooks PJ, Higuera-Rueda CA, Joyce MJ, Kattan MW, Klika AA, Krebs V, Mesko NW, Mont MA, Murray TG, Muschler GF, Nickodem RJ, Patel PD, Schaffer JL, Spindler KP, Stearns KL, Suarez JC, Zajiczek A, Molloy RM. G. Cleveland Clinic Orthopaedic Arthroplasty, The Main Predictors of Length of Stay After Total Knee Arthroplasty:
13. Burnham KP, Anderson DR, Inference M. Sociological Methods Research. 2016;33:261–304. 10.1177/0049124104268644.

14. Hoegh-Andersen P, Tanko LB, Andersen TL, Lundberg CV, Mo JA, Heegaard AM, Delaisse JM, Christgau S. Ovariectomized rats as a model of postmenopausal osteoarthritis: validation and application. Arthritis Res Ther. 2004;6:R169–80. 10.1186/ar1152.

15. Loeser RF, Olex AL, McNulty MA, Carlson CS, Callahan M, Ferguson C, Fetrow JS. Disease progression and phasic changes in gene expression in a mouse model of osteoarthritis. PLoS One. 2013;8:e54633. 10.1371/journal.pone.0054633.

16. Willis-Owen CA, Brust K, Alsop H, Miraldo M, Cobb JP. Unicondylar knee arthroplasty in the UK National Health Service: an analysis of candidacy, outcome and cost efficacy. Knee. 2009;16:473–8. 10.1016/j.knee.2009.04.006.

17. Chijimatsu R, Kunugiza Y, Taniyama Y, Nakamura N, Tomita T, Yoshikawa H. Expression and pathological effects of periostin in human osteoarthritis cartilage. BMC Musculoskelet Disord. 2015;16:215. 10.1186/s12891-015-0682-3.

18. Rodari P, Marocco S, Buonfrate D, Beltrame A, Piubelli C, Orza P, Fittipaldo VA, Bisoffi Z. Prosthetic joint infection due to Mycobacterium xenopi: a review of the literature with a new case report. Infection. 2020;48:165–71. 10.1007/s15010-019-01318-1.

19. Honsawek S, Wilairatana V, Udomsinprasert W, Sinlapavilawan P, Jirathanathornnukul N. Association of plasma and synovial fluid periostin with radiographic knee osteoarthritis: Cross-sectional study. Joint Bone Spine. 2015;82:352–5. 10.1016/j.jbspin.2015.01.023.

20. Moody RG, Williamson MP. Structure and function of a bacterial Fasciclin I Domain Protein elucidates function of related cell adhesion proteins such as TGFBIp and periostin. FEBS Open Bio. 2013;3:71–7. 10.1016/j.fob.2013.01.001.

21. Pollard B, Johnston M, Dixon D. Exploring differential item functioning in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). BMC Musculoskelet Disord. 2012;13:265. 10.1186/1471-2474-13-265.

22. Bedson J, Croft PR. The discordance between clinical and radiographic knee osteoarthritis: a systematic search and summary of the literature. BMC Musculoskelet Disord. 2008;9:116. 10.1186/1471-2474-9-116.

23. Prieto-Alhambra D, Judge A, Javaid MK, Cooper C, Diez-Perez A, Arden NK. Incidence and risk factors for clinically diagnosed knee, hip and hand osteoarthritis: influences of age, gender and osteoarthritis affecting other joints. Ann Rheum Dis. 2014;73:1659–64. 10.1136/annrheumdis-2013-203355.
Table 1. Predictors of knee osteoarthritis for model 1 (patient- and laboratory-related factors) and model 2 (laboratory-related factors).
| Variable            | Model 1          | Model 2          |
|---------------------|------------------|------------------|
|                     | OR (95% CI)      | p-value          | OR (95% CI)      | p-value          |
| **Patient-related risk factors** |                  |                  |                  |                  |
| Age                 | 1.02 (1.01 – 1.03) | <0.001**         |                  |                  |
| Sex                 |                  |                  |                  |                  |
| Female              | 0.86 (0.60 – 1.25) | 0.444            |                  |                  |
| Male                | —                | —                |                  |                  |
| BMI                 | 1.00 (0.98 – 1.02) | 0.808            |                  |                  |
| **Laboratory-related risk factors** |                  |                  |                  |                  |
| POSTN               | 1.00 (1.00 – 1.00) | 0.910            | 1.00 (1.00 – 1.00) | 0.440            |
| CRP (mg/L)          | 1.01 (0.99 – 1.02) | 0.569            | 1.00 (0.98 – 1.02) | 0.961            |
| ESR (mm/H)          | 1.00 (0.98 – 1.01) | 0.720            | 0.99 (0.97 – 1.01) | 0.317            |
| WBC                 | 1.05 (0.95 – 1.15) | 0.345            | 1.04 (0.90 – 1.19) | 0.601            |
| Neu (%)             | 0.99 (0.98 – 1.01) | 0.442            | 0.99 (0.97 – 1.01) | 0.395            |
| Hb                  | 1.00 (0.99 – 1.01) | 0.991            | 1.00 (0.98 – 1.01) | 0.763            |
| PLT                 | 1.00 (1.00 – 1.00) | 0.808            | 1.00 (0.99 – 1.00) | 0.218            |
| TP                  | 1.00 (0.96 – 1.05) | 0.937            | 1.04 (0.98 – 1.11) | 0.210            |
| ALB (g/L)           | 0.99 (0.93 – 1.06) | 0.807            | 0.93 (0.85 – 1.02) | 0.151            |
| ALT (U/L)           | 1.00 (0.98 – 1.02) | 0.839            | 0.99 (0.96 – 1.01) | 0.275            |
| AST (U/L)           | 1.00 (0.98 – 1.03) | 0.763            | 1.01 (0.97 – 1.05) | 0.594            |
| Cr (mmol/L)         | 1.00 (1.00 – 1.00) | 0.555            | 1.00 (1.00 – 1.00) | 0.633            |
| PT (S)              | 1.04 (0.86 – 1.26) | 0.677            | 1.05 (0.81 – 1.37) | 0.717            |
| INR                 | 1.03 (0.96 – 1.10) | 0.450            | 1.03 (0.93 – 1.14) | 0.571            |
| APTT (S)            | 1.03 (0.97 – 1.10) | 0.289            | 1.03 (0.95 – 1.12) | 0.504            |
| FIB                 | 1.00 (1.00 – 1.00) | 0.531            | 1.00 (1.00 – 1.01) | 0.088            |
| TT                  | 0.99 (0.98 – 1.00) | 0.227            | 1.00 (0.98 – 1.01) | 0.587            |
| FDP                 | 0.96 (0.82 – 1.12) | 0.618            | 0.90 (0.72 – 1.13) | 0.365            |
| D-dimer             | 1.00 (1.00 – 1.00) | 0.650            | 1.00 (1.00 – 1.00) | 0.388            |
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; WBC, white blood cell count; Neu%, neutrophil ratio; Hb, hemoglobin; PLT, platelet count; TP, total protein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Cr, creatinine; PT, prothrombin time; PT-A, plasma thromboplastin antecedent; INR, international normalized ratios; APTT, activated partial thromboplastin time; Fib, fibrinogen; FDP, fibrin degradation product.

Figures

![Image](image_url)

**Figure 1**

Evaluation of the OVX-OA model and periostin expression in the OVX-OA cartilage. (a) Representative images of the subchondral bone in Sham and OVX-OA rats. (b) Quantitative analysis results of BV/TV of the subchondral bone in Sham and OVX-OA rats. (c) The representative periostin immunostaining images of the OVX-OA cartilage. Right panels (c3, c4) are high magnification images of the red frame in c1 c2, respectively. (d) The semi-quantitative result of periostin expression in the OVX-OA cartilage. OA, osteoarthritis; OVX, ovariotomy; BV/TV, bone volume/ total volume; IOD, integrated optical density.
Figure 2

Periostin expression in human OA cartilage in different compartments. (a) Histological characterization of the clinical samples. Images in the black frame are the representative HE images of the areas in the red frame, bars = 250 µm. (b) Representative periostin immunostaining images of human OA cartilage. Right panels (b3 b4) are high magnification images of the red frames in b1 b2, respectively. The bars represent 100 µm in b1 b2 and 50 µm in b3 b4, respectively. (c) Semi-quantitative results of periostin expression in human cartilages. IOD, integrated optical density; M, medial compartment; L, lateral compartment; OA, osteoarthritis.
Figure 3

Correlations between plasma periostin and osteoarthritic symptoms and radiographic severity. (a) Serum levels of periostin in patients with and without OA. Value = mean ± standard error of the mean. (b) Correlations between plasma periostin and total Western Ontario and McMaster Universities Osteoarthritis Index scores. (c) Correlations between plasma periostin and pain scores. (d) Correlations between plasma periostin and function scores. (e) Correlations between plasma periostin and stiffness scores. (f) Correlations between plasma periostin and radiographic severity in all patients. OA, osteoarthritis.
Figure 4

Relative variable importance of each predictor in the full model of OA grouped by risk factors related to laboratory and patient.